BRIEF published on 02/10/2026 at 15:05, 3 months 19 days ago Sanofi Finalizes Acquisition of Dynavax Acquisition Biopharma Sanofi Vaccines Dynavax
PRESS RELEASE published on 02/10/2026 at 15:00, 3 months 19 days ago Press Release: Sanofi completes the acquisition of Dynavax Sanofi completes acquisition of Dynavax, bolstering presence in adult immunization with HEPLISAV-B vaccine and Z-1018 shingles vaccine candidate, enhancing global reach and development capabilities Acquisition Sanofi Vaccine Immunization Dynavax
BRIEF published on 02/03/2026 at 07:05, 3 months 26 days ago Sanofi Signs €1 Billion Share Buyback Mandate Share Buyback Investment Financial Strategy Biopharma Sanofi
PRESS RELEASE published on 02/03/2026 at 07:00, 3 months 26 days ago Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion Sanofi signs share buyback mandate for up to €1 billion, intending to repurchase own shares between February 3, 2026, and December 31, 2026 Share Buyback Investment Sanofi Mandate €1 Billion
BRIEF published on 01/30/2026 at 13:05, 4 months 2 days ago Sanofi's Rezurock Recommended for EU Approval by CHMP Sanofi EU Market CHMP Approval Rezurock Chronic GVHD
BRIEF published on 01/30/2026 at 13:05, 4 months 2 days ago The CHMP recommends approval of Sanofi's Rezurock for the treatment of chronic GVHD Treatment Sanofi Rezurock CHAMP GVHD
PRESS RELEASE published on 01/30/2026 at 13:00, 4 months 2 days ago Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Sanofi's Rezurock recommended for EU approval by the CHMP for chronic graft-vs-host disease treatment, based on clinical studies. New treatment option for patients Sanofi EU Approval CHMP Recommendation Rezurock Chronic GVHD
BRIEF published on 01/23/2026 at 07:05, 4 months 9 days ago Sanofi's Amlitelimab Shows Promise in Atopic Dermatitis Treatment Sanofi Atopic Dermatitis Phase 3 Studies Amlitelimab Regulatory Submissions
PRESS RELEASE published on 01/23/2026 at 07:00, 4 months 9 days ago Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis Sanofi's amlitelimab shows potential in atopic dermatitis with positive results in SHORE and COAST 2 phase 3 studies. Global regulatory submissions planned Sanofi Phase 3 Study Atopic Dermatitis Global Regulatory Submissions Amlitelimab
BRIEF published on 12/24/2025 at 07:20, 5 months 8 days ago Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio Sanofi Acquisition Dynavax Technologies HEPLISAV-B® Vaccine Shingles Candidate Adult Immunization
Published on 06/01/2026 at 14:30, 1 hour 7 minutes ago Klondike Gold Announces Receipt of Funds from Gold Royalty Payments and Warrants Exercise
Published on 06/01/2026 at 14:00, 1 hour 37 minutes ago Datametrex AI Announces Completion Of Hilco Global Patent Portfolio Qualification Review
Published on 06/01/2026 at 13:30, 2 hours 7 minutes ago Eskay Mining Corp. announces First Targets in its 5,000 meter Drill Program on its Corey-Eskay Property in British Columbia's Golden Triangle
Published on 06/01/2026 at 13:23, 2 hours 14 minutes ago SLAM Using New VTEM Survey To Generate Copper Nickel Cobalt Targets on the Goodwin Project
Published on 06/01/2026 at 15:27, 9 minutes ago North Peak Engages Independent Trading Group as Market Maker
Published on 06/01/2026 at 15:04, 32 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 06/01/2026 at 08:01, 7 hours 35 minutes ago Saint-Gobain divests HKO, a high-temperature industrial insulation textile business
Published on 06/01/2026 at 06:59, 8 hours 38 minutes ago OPmobility and Yanfeng finalize the strengthening of their Chinese joint venture YFPO
Published on 05/29/2026 at 22:00, 2 days 17 hours ago Information on the Annual Financial Statements 2025
Published on 05/29/2026 at 18:00, 2 days 21 hours ago Recticel Group acquires Isopanel NV to deliver integrated solutions in the cold storage panels market
